Breast cancer has long been considered as non‐immunogenic, yet many recent studies have demonstrated that the tumor immune infiltrate actually is of considerable clinical importance with respect to prognosis and outcome, most particularly for triple‐negative and HER2‐positive disease.15 This evidence concerns the gene ERBB2 and breast carcinoma.